BACKGROUND AND OBJECTIVE: At present, we know very little about the effectiveness of treating endoscopic ulcers in crohn's disease (CD) patients against tumor necrosis factors and the effects of disease lesions on endoscopic remission.
study aims to assess the effects of endoscopic disease activity in patients treated with INV.
method: The researchers included CD patients who were not active in the disease and CD patients with endoscopic ulcers who received IFX combined therapy in this study.
a colonoscopy at weeks 0, 12 and 54 of treatment to assess changes in the condition.
endoscopic healing is defined as the absence of ulcers and complete endoscopic remission, and the CD endoscopic severity index (CDEIS)
: The study included 122 patients (medium course time: 7 months).
the median CDEIS score for weeks 0, 12 and 54 was 9.9 (6.1-14.4), 2.4 (0.2-4.6) and 0.2 (0.0-3.7).
in weeks 12 and 54, endoscopic healing rates and endoscopic complete remission rates were 41% and 61%, 61% and 73%, respectively.
patients with deep ulcers at baseline and those with only superficial ulcers at weeks 12 and 54, the median CDEIS score was similar.
the 12th and 54th weeks of re-intestinal lesions were lower than those in the colon segment (P .lt;01).
discussion: In CD patients treated with IFX combination therapy, the severity of endoscopic lesions at baseline does not affect the cure rate, but instead the disease site affects the remission rate, and endoscopic remission occurs less frequently in the refract than in the colon.